VTVT Logo

vTv Therapeutics Inc. (VTVT) 

NASDAQ
Market Cap
$46.47M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
248 of 775
Rank in Industry
143 of 433

Largest Insider Buys in Sector

VTVT Stock Price History Chart

VTVT Stock Performance

About vTv Therapeutics Inc.

vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company is developing TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis. It is also involved in the clinical development of other programs, including TTP273, an oral small molecule …

Insider Activity of vTv Therapeutics Inc.

Over the last 12 months, insiders at vTv Therapeutics Inc. have bought $83,812 and sold $0 worth of vTv Therapeutics Inc. stock.

On average, over the past 5 years, insiders at vTv Therapeutics Inc. have bought $3.59M and sold $100,050 worth of stock each year.

Highest buying activity among insiders over the last 12 months: SEKHRI PAUL J (Pres, CEO and Exec Chairperson) — $167,624.

The last purchase of 1,844 shares for transaction amount of $31,269 was made by SEKHRI PAUL J (Pres, CEO and Exec Chairperson) on 2024‑11‑18.

List of Insider Buy and Sell Transactions, vTv Therapeutics Inc.

2024-11-18PurchasePres, CEO and Exec Chairperson
1,844
0.058%
$16.96$31,269-6.76%
2024-11-15PurchasePres, CEO and Exec Chairperson
3,156
0.1377%
$16.65$52,543-12.96%
2022-11-29Purchasedirector
40,461
0.0852%
$0.83$33,773-9.63%
2022-11-28Purchasedirector
20,539
0.0431%
$0.83$16,969-8.98%
2021-12-20Saledirector
87,000
0.154%
$1.15$100,050-26.54%
2021-02-26Purchasedirector
60,000
0.1142%
$2.86$171,600-31.58%
2021-02-26Purchasedirector
10,000
0.0182%
$2.74$27,400-31.58%
2020-12-17Purchasedirector
625,000
0.9225%
$1.60$1M-2.36%
2020-12-10Purchasedirector
625,000
0.893%
$1.60$1M-4.79%
2020-11-24Purchasedirector
625,000
1.0514%
$1.60$1M+13.44%
2020-05-15Purchasedirector
10,000
0.022%
$3.00$30,000-22.48%
2020-05-12Purchasedirector
625,000
0.8555%
$1.60$1M-8.98%
2020-02-25Purchasedirector
1.25M
1.438%
$1.60$2M-33.44%
2020-01-28Purchasedirector
1.25M
2.1109%
$1.60$2M-2.29%
2020-01-07Purchasedirector
1.25M
2.5998%
$1.60$2M+20.34%
2019-12-18Purchasedirector
1.37M
4.3437%
$1.46$2M+40.13%
2019-11-26Purchasedirector
1.37M
4.4914%
$1.46$2M+42.86%
2019-11-12Purchasedirector
1.37M
4.3437%
$1.46$2M+38.16%
2019-10-24Purchasedirector
1.37M
4.2053%
$1.46$2M+33.76%
2019-09-26Purchasedirector
1.37M
4.3232%
$1.46$2M+45.83%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.